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Forward 5 Figure S3 . RepresentaDve clinical course of a paDent who had mutant KRAS alleles (G12V) preoperaDvely detected in plasma.
CT images examined at the same Dme of plasma sampling (A), 3 months aRer the operaDon (B) and 2 months aRer the chemotherapy (C). PreoperaDve CT image (A) showed cysDc lesions in the pancreas (main pancreaDc tumor was detected as a 19 mm mass on other slices), while space--occupying lesion of the right lobe of the liver was not detected. ARer the operaDon, space--occupying lesion of the right lobe of the liver (red arrow) was detected (B) and increased in size (C) by CT scan. The paDent died of the cancer 9 months aRer the operaDon. The CA19--9 and CEA levels were assessed during therapies. Red arrows, metastaDc tumor in the liver. WT, wild--type; GEM, gemcitabine. Tumor 5ssue
Supplementary Figure S6 . Sanger sequencing analysis for KRAS and PBRM1 in the primary cancer and the matched normal 5ssue (Pa5ent ID--18). The same muta5ons as those were detected in plasma cfDNA were observed in the corresponding tumor 5ssue.
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